Literature DB >> 10738269

Prognostic significance of immunohistochemical micrometastases in node negative gastric cancer patients.

L E Harrison1, J K Choe, M Goldstein, A Meridian, S H Kim, K Clarke.   

Abstract

BACKGROUND AND OBJECTIVES: The purpose of this study is to examine the prognostic significance of immunohistochemical (IHC) evidence of lymph node (LN) metastases in histologic node negative gastric cancer patients.
METHODS: Retrospective review from 1981 to 1998 revealed 25 patients resected for T1-4N0M0 gastric and gastroesophageal (GE) junction adenocarcinoma. All cases were reviewed and histopathologic parameters were defined for each primary tumor. All LNs underwent IHC analysis with the epithelial marker CAM 5.2. Data are reported as median (range).
RESULTS: The median number of LN resected was 7 (range 1-33). The median follow-up time was 25 months (range 4-195) with an overall 5-year survival rate of 55%. For patients with IHC evidence of LN micrometastasis (n = 9), the 5-year survival rate was significantly decreased (35%) compared to a 66% 5-year survival rate for IHC negative patients (n = 16, P = 0.05).
CONCLUSIONS: The presence of IHC-detected LN micrometastases correlates with worse prognosis for patients with histologic node negative gastric cancer. IHC may be a useful additional staging modality in this subset of patients.

Entities:  

Mesh:

Year:  2000        PMID: 10738269     DOI: 10.1002/(sici)1096-9098(200003)73:3<153::aid-jso8>3.0.co;2-4

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  20 in total

1.  Intraoperative diagnosis of lymph node metastasis by transcription-reverse transcription concerted reaction assay in gastric cancer.

Authors:  Ryouichi Hirayama; Akiyoshi Seshimo; Kunitomo Miyake; Masako Nishizawa; Shingo Kameoka
Journal:  Int J Clin Oncol       Date:  2013-06-14       Impact factor: 3.402

2.  Orthotopic transplantation model of human gastrointestinal cancer and detection of micrometastases.

Authors:  J H Cui; U Krueger; D Henne-Bruns; B Kremer; H Kalthoff
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

3.  Do we have enough evidence for expanding the indications of ESD for EGC?

Authors:  Hang Lak Lee; Chang Hwan Choi; Dae Young Cheung
Journal:  World J Gastroenterol       Date:  2011-06-07       Impact factor: 5.742

4.  Occult Tumour Cells in Lymph Nodes from Gastric Cancer Patients: Should Isolated Tumour Cells Also Be Considered?

Authors:  A Tavares; X Wen; J Maciel; F Carneiro; M Dinis-Ribeiro
Journal:  Ann Surg Oncol       Date:  2020-05-04       Impact factor: 5.344

Review 5.  Detection and clinical implications of minimal residual disease in gastro-intestinal cancer.

Authors:  Fabian Wolfrum; Ilka Vogel; Fred Fändrich; Holger Kalthoff
Journal:  Langenbecks Arch Surg       Date:  2005-07-01       Impact factor: 3.445

Review 6.  N staging: the role of the pathologist.

Authors:  Costanza De Marco; Alberto Biondi; Riccardo Ricci
Journal:  Transl Gastroenterol Hepatol       Date:  2017-02-20

7.  Vascularizing lymph node dissection for advanced gastric cancer: A single-institution experience.

Authors:  Fang-Hai Han; Sheng-Ning Zhou; Hong-Ming Li; Yu-Long He; Wen-Hua Zhan
Journal:  World J Gastroenterol       Date:  2016-04-14       Impact factor: 5.742

8.  Gastric carcinoma: stage migration by immunohistochemically detected lymph node micrometastases.

Authors:  Theresa L A Jeuck; Christian Wittekind
Journal:  Gastric Cancer       Date:  2014-02-19       Impact factor: 7.370

Review 9.  Lymph node micrometastasis in gastrointestinal tract cancer--a clinical aspect.

Authors:  Shoji Natsugoe; Takaaki Arigami; Yoshikazu Uenosono; Shigehiro Yanagita; Akihiro Nakajo; Masataka Matsumoto; Hiroshi Okumura; Yuko Kijima; Masahiko Sakoda; Yuko Mataki; Yasuto Uchikado; Shinichiro Mori; Kosei Maemura; Sumiya Ishigami
Journal:  Int J Clin Oncol       Date:  2013-06-18       Impact factor: 3.402

10.  Significance of isolated tumor cells in lymph nodes among gastric cancer patients.

Authors:  Olaf Horstmann; Laszlo Füzesi; Peter M Markus; Carola Werner; Heinz Becker
Journal:  J Cancer Res Clin Oncol       Date:  2004-09-17       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.